enGenes secure significant funding for ECOnti E. coli Continuous Manufacturing Project
News-ReleasesEnGenes Biotech GmbH
May 3rd 2023
Vienna, Austria: – The Austrian Research Funding Agency (FFG) has awarded significant funding to recombinant proteins specialist CDMO enGenes Biotech GmbH (enGenes) to lead a consortium to advance continuous manufacturing based on Escherichia coli (E. coli).
The FFG has committed to providing total funding of 2.7 Million EUR for the ECOnti project, which has been estimated to have total costs of 3.6 Million EUR to reach the final process.
The project “ECOnti – Accelerated, low ecological footprint, manufacturing platform for continuous production of biotechnological products” aims to develop a fully integrated and automated continuous upstream and downstream process at up to 10 L batch size.
This small-scale development platform will enable the industry to develop continuous bioprocesses and implement model predictive control and the consortium will also perform economic modelling to showcase potential cost-savings of continuous manufacturing vs. batch-based manufacturing.
Initial life-cycle engineering (LCE) economic analysis has indicated substantial potential bioprocess operating cost advantages when compared with discontinuous batch processes.
For more information follow https://www.pharmaceutical-networking.com/engenes-secure-significant-funding-for-econti-e-coli-continuous-manufacturing-project/
